Participants in the 2009 NEI/FDA Clinical Trial Endpoints Symposium [Commercial Relationship Disclosure]
Dimitri T. Azar, Head, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL [Bausch & Lomb (C), Alcon Laboratories (C), Allergan (C), Foresight (C), Sarentis (C), Prism Ventures (C)]
Neil M. Bressler, Chief, Retina Division, Johns Hopkins University, Baltimore, MD [Allergan (F) Bausch & Lomb (F), Bristol-Meyers Squibb (F), Carl Zeiss Meditec (F), EMMES Corporation (F), Genentech (F), Lumenis (F), Notal Vision (F), Novartis (F), Othera (F), QLT (F), Regeneron (F), Steba Biotech (F)]
Laurie B. Burke, Director, Study Endpoints and Label Development, Office of New Drugs, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD [None]
Wiley A. Chambers, Acting Director, Division of anti-Infective and Ophthalmology Products, CDER, FDA [None]
Anne L. Coleman, University of California, Los Angeles [Alcon (C), Allergan (C), Pfizer (C), Science-based Health (C)]
Malvina Eydelman, Director, Division of Ophthalmic and Ear, Nose and Throat Devices, Center for Device and Radiologic Health (CDRH), FDA [None]
Frederick L. Ferris III, Clinical Director, National Eye Institute (NEI), Bethesda, MD [None]
Suber S. Huang, Director, Vitreoretinal Diseases and Surgery, University Hospitals/Case Western Reserve University, Cleveland, OH [Bausch & Lomb Surgical (C); Merck & Co., Inc. (C); SurModics, Inc. (C, I); Second Sight (C); Therapeutic Nanoparticle and Molecular Imaging (C); Digital Healthcare, Inc. (C, I); i2i Innovative Ideas, Inc. (E); as Director of the Case Western Reserve REDIARC (Retinal Diseases Image Analysis Reading Center): Neurotech (C), Lux Bio (C), Alcon (C), Pfizer (C), Shering Plough (C), Vitreo Retinal Technologies, (C) MacuSight (C)]
Paul P. Lee, Vice Chairman, Duke University Eye Center, Durham, NC [Alcon (C, R, F), Allergan (C, R, F), Pfizer (C, R, F, I), Genentech (C, F)]
Nancy K. Leidy, Senior Vice President, Scientific Affairs, United BioSource Corporation, Bethesda, MD [None]
Anne S. Lindblad, Executive Vice President, The EMMES Corporation, Rockville, MD [The EMMES Corporation (F)]
Danica Marinac-Dabic, Director, Division of Epidemiology, CDRH, FDA [None]
Peter J. McDonnell, Director, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD [None]
Timothy T. McMahon, Director of Contact Lens Service, University of Illinois, Chicago, IL [Bausch & Lomb, Inc. (C), Vistakon, Inc. (C)]
Päivi Miskala, Study Endpoints Reviewer, Study Endpoints and Label Development, CDER, FDA [None]
William L. Rich III, Falls Church, VA [None]
Paul A. Sieving, Director, NEI [None]
Roger F. Steinert, Vice Chairman of Clinical Ophthalmology, and Director of Refractive, Cornea, and Cataract Surgery, Gavin Herbert Eye, Institute University of California, Irvine, CA [Abbott Medical Optics (C)]
Rohit Varma, Director, Glaucoma Service, Doheny Eye Institute, University of Southern California, Los Angeles, CA [Allergan (C), Pfizer and Alcon Laboratories (C), Optovue (C), Aquesys (C, I), Laboratorios Sophia (C), Bausch & Lomb Surgical (C), Merck (C), Replenish (C, I)]
Susan Vitale, Research Epidemiologist, Division of Epidemiology and Clinical Applications, NEI [None]
Robert N. Weinreb, Director, Hamilton Glaucoma Center, University of California, San Diego, CA [Aciex (C, R, F), Alcon (C, R, F), Allergan (C, R, F), GlaxoSmithKline (C, R, F), Merck (C, R, F), Optovue (C, R, F), Pfizer (C, R, F), Topcon (C, R, F), Carl Zeiss Meditec (C, R, F), Heidelberg Engineering (C, R, F), Novartis (C, R, F)]